Deals
Sanofi Gets Binding Bids from CD&R, PAI for Consumer Arm
- Buyout firms submitted separate offers by Monday deadline
- Sanofi’s OTC arm could be valued at €15 billion or more
Sanofi is likely to make a final decision on the unit in the coming days after reviewing the offers.
Photographer: Nathan Laine/BloombergThis article is for subscribers only.
Sanofi has received binding offers for its consumer health division from private equity firms Clayton Dubilier & Rice and PAI Partners, as the French drugmaker inches closer to one of the largest European deals this year, according to people familiar with the matter.
The two buyout firms made separate bids for the business by Monday’s deadline, the people said. Sanofi is likely to make a final decision on the unit in the coming days after reviewing the offers, which could value the unit at €15 billion ($16.7 billion) or more, the people said.